{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-093348","form_type":"8-K","ticker":"PEPG","cik":"0001835597","company_name":"PepGen Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.799994+00:00","generated_at":"2026-05-31T11:13:12.664830+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"PepGen reports Q2 2024 net loss $28.3M; PGN-EDO51 shows 2.15% exon skipping in CONNECT1","bullets":["Net loss $28.3M ($0.87/sh) for Q2 2024 vs $19.5M ($0.82/sh) YoY; cash $161.3M, runway into 2026.","PGN-EDO51 (DMD) 5mg/kg cohort: mean exon skipping 2.15%, dystrophin increase 0.70% (muscle-adjusted) from baseline; well tolerated.","FREEDOM-DM1 Phase 1 results expected Q4 2024; FREEDOM2-DM1 cleared by Health Canada & MHRA, dosing H2 2024.","PGN-EDO53 (DMD) advancing in IND/CTA-enabling studies."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-093348","json":"https://secwatch.observer/filing/0000950170-24-093348.json","markdown":"https://secwatch.observer/filing/0000950170-24-093348.md","text":"https://secwatch.observer/filing/0000950170-24-093348.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835597/000095017024093348/0000950170-24-093348-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835597/000095017024093348/pepg-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:13:12.664830+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}